Reported about 1 month ago
Ro's CEO Zach Reitano points out that the rise of compounded GLP-1 medications is a reflection of significant supply shortages faced by major pharmaceutical companies like Novo Nordisk and Eli Lilly. As competition in the weight-loss drug market increases, the compounded versions have become essential for many patients who either cannot access branded medications or find them unaffordable. Reitano emphasizes that while compounding is important, it signals broader pharmaceutical accessibility issues that need to be addressed.
Source: YAHOO